Beyond the edge of hypomethylating agents: novel combination strategies for older adults with advanced MDS and AML
AS Kubasch, U Platzbecker - Cancers, 2018 - mdpi.com
Higher-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) of the
elderly exhibit several commonalities, including first line treatment with hypomethylating …
elderly exhibit several commonalities, including first line treatment with hypomethylating …
Age at diagnosis and patient preferences for treatment outcomes in AML: a discrete choice experiment to explore meaningful benefits
DR Richardson, NL Crossnohere, J Seo, E Estey… - … Biomarkers & Prevention, 2020 - AACR
Background: The recent expansion of treatment options in acute myeloid leukemia (AML)
has necessitated a greater understanding of patient preferences for treatment benefits …
has necessitated a greater understanding of patient preferences for treatment benefits …
A kinase inhibitor with anti-Pim kinase activity is a potent and selective cytotoxic agent toward acute myeloid leukemia
R Bjørnstad, R Aesoy, Ø Bruserud, AK Brenner… - Molecular Cancer …, 2019 - AACR
More than 40 years ago, the present standard induction therapy for acute myeloid leukemia
(AML) was developed. This consists of the metabolic inhibitor cytarabine (AraC) and the …
(AML) was developed. This consists of the metabolic inhibitor cytarabine (AraC) and the …
Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: analysis of survival after 'CLAG …
CJ Scheckel, M Meyer, JA Betcher, A Al-Kali, J Foran… - Leukemia Research, 2020 - Elsevier
Salvage therapy regimens for refractory and relapsed AML include mitoxantrone, etoposide,
and cytarabine (MEC) and cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) …
and cytarabine (MEC) and cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) …
Hyaluronan in the Extracellular Matrix of Hematological and Solid Tumors. Its Biological Effects
A Icardi, SL Lompardia, DL Papademetrio… - The Extracellular Matrix …, 2022 - Springer
Tumors are most frequently induced by environmental factors with oncogenic potential.
Beside tumor cells, cancer tissue contains several nonmalignant cells with well-defined …
Beside tumor cells, cancer tissue contains several nonmalignant cells with well-defined …
[PDF][PDF] Contribution value of akt, c-myc, cip2a, and pp2a genes expression in leukemogenesis: a bright perspective on the molecular pattern of patients with acute …
M Sayyadi, A Safaroghli-Azar, S Rabiemajd… - International Journal of …, 2020 - brieflands.com
Background: The heterogeneous nature of acute myeloid leukemia (AML) and the hurdle to
find a suitable treatment strategy for this malignancy put this type of leukemia at the top of …
find a suitable treatment strategy for this malignancy put this type of leukemia at the top of …
[PDF][PDF] Wilms' tumor gene (WT1) expression in cytogenetically distinct subsets of AML
S Qazi, U FM - J Blood Transfus Hematop, 2018 - researchgate.net
The Wilms' tumor gene (WT1)[1-3] is a tumor-suppressor gene associated with Wilms' tumor,
a pediatric kidney cancer. The protein product of the WT1 gene is a zinc-finger transcription …
a pediatric kidney cancer. The protein product of the WT1 gene is a zinc-finger transcription …